Extending the Time for Thrombolysis in Emergency Neurological Deficits "EXTEND"
Recruiting
Phase 3 Results N/ASummary of Purpose
The primary hypothesis being tested in this trial is that ischaemic stroke patients selected with significant penumbral mismatch (measured by MRI criteria) at 3 - 9 hours post onset of stroke will have improved clinical outcomes when given intravenous tissue plasminogen activator (tPA) compared to placebo.
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 30 April 2013.
| 1 Jun 2010 | 22 Apr 2009 | 1 Dec 2014 | Unavailable | 1 Apr 2013 | Unavailable |
| Start Date | First Received | 1st Completion | Completion | Verification | Results |
|---|
Trial Design
- Allocation: Randomized
- Masking: Double Blind (Subject, Caregiver, Investigator)
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Contacts
- Sue Bates, BSc(Hons)
sbates@neurotrialsaustralia.com +61 3 9035 7230
View Trial Locations
Recruitment
- Enrollment: 400
- Gender: Both
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 18 locations, 2 countries
Principal Investigator
- Geoffrey Donnan, MD FRACP
National Stroke Research Institute, Australia
- Stephen Davis, MD FRACP
University of Melbourne
